CMS5 Syngeneic Model Overview
The CMS5 syngeneic model is a murine fibrosarcoma system derived from BALB/c mice and represents a well-characterized, immunogenic soft tissue sarcoma frequently employed in immuno-oncology research. Originally established from a chemically induced tumor, CMS5 exhibits reproducible growth, robust immune interaction, and moderate aggressiveness. It has been widely used in preclinical studies investigating tumor immunity, cytokine biology, and the development of novel immunotherapies.
When implanted subcutaneously or intramuscularly, CMS5 cells form solid, vascularized tumors that display consistent progression and measurable immune infiltration. The model’s immunocompetent BALB/c host background allows detailed evaluation of immune checkpoint inhibitors, macrophage modulation, and combination therapy strategies aimed at enhancing anti-tumor immune responses. CMS5 serves as a key tool in translational studies of immune regulation and tumor microenvironment dynamics.
Request a Custom Quote for CMS5 Syngeneic ModelBiological and Molecular Characteristics
The CMS5 cell line originated from a methylcholanthrene-induced fibrosarcoma in a BALB/c mouse and has since been extensively used in immunology and tumor immunotherapy research. CMS5 cells exhibit spindle-shaped fibroblast-like morphology typical of fibrosarcoma and express vimentin, confirming mesenchymal origin. The tumor secretes a variety of cytokines, including IL-6, TGF-beta, and VEGF, contributing to angiogenesis and immune modulation.
CMS5 is moderately immunogenic, capable of eliciting both innate and adaptive immune responses while maintaining progressive tumor growth under normal conditions. The tumor microenvironment contains macrophages, dendritic cells, fibroblasts, and lymphocytes, with infiltration by CD8-positive T cells that can be further enhanced by immune activation or cytokine therapy. These features make CMS5 particularly well suited for studies examining the balance between immune suppression and stimulation in fibrosarcoma.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Chemically induced fibrosarcoma (mouse) |
| Histological type | Fibrosarcoma |
| Inoculation route | Subcutaneous or intramuscular |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–5 days in vivo |
| Metastatic potential | Low; localized invasion only |
| Immunophenotype | Moderately immunogenic; macrophage and lymphocyte infiltration |
| Common applications | Immunotherapy, cytokine research, macrophage activation, checkpoint blockade studies |
In Vivo Model Development and Tumorigenicity
CMS5 tumors can be reliably established by subcutaneous or intramuscular inoculation of viable tumor cells into immunocompetent BALB/c mice. Subcutaneous implantation produces solid, measurable tumors within 5–7 days, making it well suited for monitoring therapeutic efficacy and tumor regression. Intramuscular inoculation provides a more physiologic stromal environment and is frequently used for mechanistic studies of immune infiltration and tumor–stroma interactions.
CMS5 tumors exhibit moderate growth kinetics and predictable progression, allowing for reproducible experimental timelines. Because the model’s immune activity can be modulated through cytokine or checkpoint blockade therapies, it is particularly useful for evaluating combination immunotherapies and novel immune adjuvants. Its consistent tumor take rate and immune-competent background provide a robust platform for translational research in fibrosarcoma immunology.
Request a Custom Quote for CMS5 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination of CMS5 tumors reveals densely packed spindle cells arranged in interlacing fascicles, typical of fibrosarcoma. The tumors show moderate vascularization and focal necrosis surrounded by viable proliferative zones. Collagen deposition within the stroma and the presence of immune infiltrates contribute to the characteristic fibrotic and immune-active tumor architecture.
Immunohistochemical staining demonstrates strong vimentin expression, consistent with mesenchymal differentiation. Ki-67 staining indicates high proliferative activity, while CD31 highlights the vascular endothelium. CD3 and CD8 staining reveal significant T-cell presence, particularly at the tumor periphery, and F4/80 identifies macrophages distributed throughout the stroma. PD-L1 expression is moderate and increases under cytokine stimulation or immunotherapy. Collectively, these histological and immunological features underscore CMS5’s relevance as a representative fibrosarcoma model for immune-targeted research.
Preclinical Applications and Drug Response
The CMS5 syngeneic model has been a cornerstone in preclinical immunotherapy research, particularly for testing immune checkpoint inhibitors, cytokine-based therapies, and macrophage-targeted drugs. It is responsive to IL-2, IFN-gamma, and TNF-alpha, as well as to combination treatments integrating immune activation and cytotoxic therapy. CMS5 tumors demonstrate partial regression in response to PD-1 and CTLA-4 blockade, making this model suitable for mechanistic studies of T-cell activation and immune resistance.
This model is also widely applied in vaccine development and immune memory studies, as tumor-bearing mice can develop long-lasting immunity after successful treatment or tumor rejection. CMS5’s well-defined immunogenicity, reproducibility, and translational relevance make it a preferred system for exploring how immunomodulatory therapies reshape the tumor microenvironment and promote durable anti-tumor immunity.
Request This Model
To request the CMS5 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for CMS5 Syngeneic Model